Viatris (VTRS) Cash from Operations Growth (1y) (2020 - 2026)
Viatris (VTRS) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 425.00% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 450.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.49% |
| Dec 31, 2025 | 69.01% |
| Sep 30, 2025 | -9.87% |
| Jun 30, 2025 | -42.05% |
| Mar 31, 2025 | -12.87% |
| Dec 31, 2024 | -15.09% |
| Sep 30, 2024 | -1.04% |
| Jun 30, 2024 | -27.80% |
| Mar 31, 2024 | -36.72% |
| Dec 31, 2023 | 200.79% |
| Sep 30, 2023 | -3.89% |
| Jun 30, 2023 | -34.57% |
| Mar 31, 2023 | -14.69% |
| Dec 31, 2022 | -63.87% |
| Sep 30, 2022 | -19.95% |
| Jun 30, 2022 | 43.46% |
| Mar 31, 2022 | 34.13% |
| Dec 31, 2021 | 1,345.03% |
| Mar 31, 2021 | 191.58% |
| Dec 31, 2020 | -97.99% |